New Safety Information - Food and Drug Administration

Close

GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us

Menu

GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us

Home
About FDA
Transparency
Issuances
Services
- eServices
- ePortal
- ePortal2
- BOSS
- Doctrack

Menu

Home
About FDA
Transparency
Issuances
Services
- eServices
- ePortal
- ePortal2
- BOSS
- Doctrack

New Safety Information

2019

Incorrect Use of Anti-Fungal Corticosteroid Combination Therapy
Unsafe use of glutathione as skin lightening agent
SGLT2 inhibitors and risk of necrotizing fasciitis of the perineum (Fournier’s gangrene)
Fluoroquinolones and risk of aortic aneurysm and dissection

Quick Menus

Recent Posts

FDA Advisory No.2022-0018 || Public Health Warning Against the Purchase…
FDA Advisory No.2022-0017 || Public Health Warning Against the Purchase…
FDA Advisory No.2022-0016 || Public Health Warning Against the Purchase…
FDA Advisory No.2022-0019 || Public Health Warning Against the Purchase…

Quick Links

Department of Health (DOH)
U.S Food and Drug Administration (U.S FDA)
Department of Information and Communications Technology (DICT)
Department of Science and Technology (DOST)
Anti-Red Tape Authority (ARTA)

Contact Information

Address:

Civic Drive Filinvest Corporate City

Alabang, Muntinlupa City

Tel. no: +632 8 857-1900

[email protected]

Landline:

(8) 821-1177
(8) 821-1176
(8) 821-1220
(8) 821-1162
(8) 821-1159

Mobile:

0961-6804447
0961-7709691
0961-6845994

Email: [email protected]

Copyright © 2022. All Rights Reserved.